tradingkey.logo


Fulgent Genetics Inc

FLGT
26.720USD
-0.290-1.07%
āļ›āļīāļ” 12/26, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
824.42MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Fulgent Genetics Inc āļšāļĢāļīāļĐāļąāļ—

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

āļ‚āđ‰āļ­āļĄāļđāļĨ Fulgent Genetics Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™FLGT
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Fulgent Genetics Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 28, 2016
āļ‹āļĩāļ­āļĩāđ‚āļ­Hsieh (Ming)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™1313
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Sep 28
āļ—āļĩāđˆāļ­āļĒāļđāđˆ4399 Santa Anita Ave
āđ€āļĄāļ·āļ­āļ‡EL MONTE
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ91731
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ16263500537
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.fulgentgenetics.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™FLGT
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 28, 2016
āļ‹āļĩāļ­āļĩāđ‚āļ­Hsieh (Ming)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Fulgent Genetics Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.76M
-0.06%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
869.55K
-0.12%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
228.63K
-0.49%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
213.20K
-0.53%
Ms. Linda Marsh
Ms. Linda Marsh
Independent Director
Independent Director
18.11K
+98.39%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
12.23K
+276.37%
Dr. Michael Nohaile, Ph.D.
Dr. Michael Nohaile, Ph.D.
Independent Director
Independent Director
10.51K
+74.68%
Ms. Melanie Solomon
Ms. Melanie Solomon
Investor Relations
Investor Relations
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Ming Hsieh
Mr. Ming Hsieh
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.76M
-0.06%
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Dr. Hanlin (Harry) Gao, M.D., Ph.D.
Chief Scientific Officer, Laboratory Director
Chief Scientific Officer, Laboratory Director
869.55K
-0.12%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Chief Financial Officer
Chief Financial Officer
228.63K
-0.49%
Mr. Jian (James) Xie
Mr. Jian (James) Xie
President, Chief Operating Officer
President, Chief Operating Officer
213.20K
-0.53%
Ms. Linda Marsh
Ms. Linda Marsh
Independent Director
Independent Director
18.11K
+98.39%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
12.23K
+276.37%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Institutional
45.62M
55.77%
Insurance
34.38M
42.03%
Patient
1.80M
2.20%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
76.21M
93.16%
Foreign
5.60M
6.84%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Institutional
45.62M
55.77%
Insurance
34.38M
42.03%
Patient
1.80M
2.20%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 15 āļž.āļĒ.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 15 āļž.āļĒ.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Hsieh (Ming)
28.33%
BlackRock Institutional Trust Company, N.A.
6.45%
Millennium Management LLC
4.75%
The Vanguard Group, Inc.
3.80%
Acadian Asset Management LLC
3.69%
āļ­āļ·āđˆāļ™ āđ†
52.99%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Hsieh (Ming)
28.33%
BlackRock Institutional Trust Company, N.A.
6.45%
Millennium Management LLC
4.75%
The Vanguard Group, Inc.
3.80%
Acadian Asset Management LLC
3.69%
āļ­āļ·āđˆāļ™ āđ†
52.99%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Individual Investor
32.70%
Investment Advisor/Hedge Fund
20.23%
Investment Advisor
19.92%
Hedge Fund
12.93%
Research Firm
3.36%
Bank and Trust
0.30%
Sovereign Wealth Fund
0.28%
Pension Fund
0.21%
Venture Capital
0.05%
āļ­āļ·āđˆāļ™ āđ†
10.02%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
412
16.53M
59.35%
--
2025Q3
439
16.53M
59.80%
-4.75K
2025Q2
463
16.58M
62.72%
-126.14K
2025Q1
472
16.61M
64.18%
-3.20M
2024Q4
474
17.50M
62.81%
+892.69K
2024Q3
488
16.58M
60.31%
+907.77K
2024Q2
524
15.67M
60.02%
+492.38K
2024Q1
543
15.20M
57.74%
-2.06M
2023Q4
574
14.77M
58.48%
+87.68K
2023Q3
579
14.65M
57.50%
+460.38K
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Hsieh (Ming)
8.76M
28.62%
-6.40K
-0.07%
Aug 26, 2025
BlackRock Institutional Trust Company, N.A.
1.62M
5.3%
-69.12K
-4.09%
Jun 30, 2025
Millennium Management LLC
1.44M
4.71%
--
--
Jul 29, 2025
The Vanguard Group, Inc.
1.16M
3.79%
-4.25K
-0.37%
Jun 30, 2025
Acadian Asset Management LLC
1.12M
3.65%
+311.98K
+38.71%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.13M
3.71%
+105.42K
+10.25%
Jun 30, 2025
Gao (Hanlin)
873.75K
2.85%
-1.06K
-0.12%
Sep 03, 2025
BlackRock Financial Management, Inc.
280.92K
0.92%
-4.69K
-1.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
476.49K
1.56%
+36.47K
+8.29%
Jun 30, 2025
DWS Investments UK Limited
330.56K
1.08%
+112.51K
+51.60%
Jun 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
State Street SPDR S&P Health Care Services ETF
0.72%
Global X Genomics & Biotechnology ETF
0.5%
ALPS Medical Breakthroughs ETF
0.28%
iShares US Small Cap Value Factor ETF
0.23%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.08%
iShares U.S. Healthcare Providers ETF
0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
Goldman Sachs Innovate Equity ETF
0.05%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
State Street SPDR S&P Health Care Services ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.72%
Global X Genomics & Biotechnology ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.5%
ALPS Medical Breakthroughs ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.28%
iShares US Small Cap Value Factor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.23%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.08%
iShares U.S. Healthcare Providers ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.07%
iShares MSCI USA Small-Cap Min Vol Factor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.07%
Invesco RAFI US 1500 Small-Mid ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.06%
Avantis US Small Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.05%
Goldman Sachs Innovate Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.05%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Fulgent Genetics Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Fulgent Genetics Inc āđ„āļ”āđ‰āđāļāđˆ:
Hsieh (Ming) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 8.76M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 28.62% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
BlackRock Institutional Trust Company, N.A. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 1.62M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 5.30% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Millennium Management LLC āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 1.44M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 4.71% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
The Vanguard Group, Inc. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 1.16M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 3.79% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Acadian Asset Management LLC āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 1.12M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 3.65% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”

āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Fulgent Genetics Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Fulgent Genetics Inc āđ„āļ”āđ‰āđāļāđˆ
Hsieh (Ming)
BlackRock Institutional Trust Company, N.A.
Millennium Management LLC

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Fulgent Genetics Inc (FLGT)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2025Q4 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 412 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Fulgent Genetics Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 16.53M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 59.35% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q3 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -0.46%

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ Fulgent Genetics Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ FY2025Q2 āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ Institutional āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš Fulgent Genetics Inc āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē 45.62M āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 55.77% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
KeyAI
î™